Summary & Overview
HCPCS Level II A4641: Radiopharmaceutical, Diagnostic, Not Otherwise Classified
HCPCS Level II code A4641 denotes a diagnostic radiopharmaceutical classified as "not otherwise classified." Nationally, this code is used when a diagnostic imaging agent lacks a more specific HCPCS descriptor, making it relevant for billing of novel or uncommon radiotracers used in nuclear medicine and molecular imaging. The code matters because radiopharmaceuticals are central to diagnostic pathways for oncology, cardiology, neurology and other specialties that rely on functional imaging, and accurate coding affects claims processing and clinical documentation.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of the code’s clinical role and service setting, plus benchmarking context where available. The publication highlights common payer coverage considerations and coding scenarios, summarizes typical sites of service for administration, and identifies where additional coding specificity may be required.
This analysis provides clinicians, coding staff, and revenue cycle professionals with practical context about when A4641 is applied, the types of diagnostic procedures it supports, and the national payer landscape relevant to diagnostic radiopharmaceutical billing. Data not provided in the input (such as associated taxonomies, ICD-10 pairings, or detailed payer-specific reimbursement rates) is noted as unavailable.
Billing Code Overview
HCPCS Level II code A4641 is defined as Radiopharmaceutical, diagnostic, not otherwise classified. This code represents a diagnostic radiopharmaceutical agent that does not fall under a more specific HCPCS Level II descriptor. These agents are used to visualize physiological processes or target-specific molecular activity for diagnostic imaging.
Service type: Diagnostic radiopharmaceutical administration
Typical site of service: Hospital outpatient imaging centers, nuclear medicine departments, and outpatient radiology clinics
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with a known history of prostate cancer is referred for a diagnostic nuclear medicine study using a specialized radiopharmaceutical not otherwise classified (A4641) to evaluate suspected metastatic disease. The patient arrives at an outpatient nuclear medicine clinic or hospital radiology department. After registration and verification of allergies and pregnancy status, a nuclear medicine technologist confirms the radiopharmaceutical dose and prepares the tracer under institutional radiation safety protocols. The radiopharmaceutical labeled under A4641 is administered intravenously, with exact timing documented for image acquisition. The patient rests in a monitored uptake room for the appropriate biodistribution interval. Imaging is performed by a nuclear medicine technologist and interpreted by a nuclear medicine physician or radiologist. Post-procedure, the interpreting physician documents findings and a final report is issued for the referring oncologist.
Typical site of service: outpatient nuclear medicine department, hospital radiology or ambulatory imaging center.
Typical patient scenario: diagnostic evaluation for occult or metastatic disease, biochemical recurrence surveillance, or localization of disease when standard radiopharmaceuticals are not appropriate or available.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|